查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1344472

老龄化黄斑部病变(AMD)市场:各药物类型，各疾病类型，各流通管道:全球机会分析与产业预测，2023-2032年

Age Related Macular Degeneration Market By Drug Type, By Disease Type (Wet Age Related Macular Degeneration, Dry Age Related Macular Degeneration ), By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2023-2032
出版日期: | 出版商: Allied Market Research | 英文 251 Pages | 商品交期: 2-3个工作天内

价格

2022 年，年龄相关性黄斑部病变 (AMD) 市值为 94 亿美元，预计 2023 年至 2032 年复合年增长率为 5%，到 2032 年达到 154 亿美元。

老年黄斑部病变市场-IMG1

然而，与老年性黄斑部病变 (AMD) 治疗相关的高成本预计将阻碍未来的市场成长。相反，年龄相关性黄斑部病变（AMD）治疗领域不断增加的研发活动和最新产品的批准预计将在不久的将来为市场成长提供有利的机会。

目录

第1章 简介

第2章 摘要整理

第3章 市场概要

  • 市场定义和范围
  • 主要调查结果
    • 影响要素
    • 主要的投资机会
  • 波特的五力分析
    • 供给企业谈判力
    • 买方议价能力
    • 替代品的威胁
    • 新加入厂商业者的威胁
    • 竞争激烈度
  • 市场动态
    • 促进因素
      • 老人人口的增加
      • 全球老龄化黄斑部病变(AMD)的增加
    • 阻碍因素
      • 高额的治疗费
    • 机会
      • 开发平台(管线)医药品的增加
  • COVID-19:对市场的影响分析

第4章 老龄化黄斑部病变(AMD)市场:各药物类型

  • 概要
  • 阿柏西普
  • 雷珠单抗
  • 其他

第5章 老龄化黄斑部病变(AMD)市场:各疾病类型

  • 概要
  • 渗出型AMD
  • 萎缩型AMD

第6章 老龄化黄斑部病变(AMD)市场:各流通管道

  • 概要
  • 医院药局
  • 零售药局
  • 线上药局

第7章 老龄化黄斑部病变(AMD)市场:各地区

  • 概要
  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 法国
    • 德国
    • 义大利
    • 西班牙
    • 英国
    • 其他欧洲
  • 亚太地区
    • 中国
    • 日本
    • 澳洲
    • 印度
    • 韩国
    • 其他亚太地区
  • 南美·中东·非洲
    • 巴西
    • 沙乌地阿拉伯
    • 南非
    • 其他地区

第8章 竞争情形

  • 简介
  • 主要成功策略
  • 主要10企业的产品製图
  • 竞争仪表板
  • 竞争热图
  • 主要企业的定位，2022年

第9章 企业简介

  • Regeneron Pharmaceuticals Inc.
  • Novartis AG
  • F. Hoffmann-La Roche Ltd.
  • Biogen
  • Bayer AG
  • Coherus Biosciences Inc
  • Sanofi S.A.
  • Apellis Pharmaceuticals Inc.
  • Bausch Health Companies Inc.
  • Ionis Pharmaceuticals, Inc.
Product Code: A03198

According to a new report published by Allied Market Research, titled, "Age Related Macular Degeneration (AMD) Market," The age related macular degeneration (amd) market was valued at $9.4 billion in 2022, and is estimated to reach $15.4 billion by 2032, growing at a CAGR of 5% from 2023 to 2032.

Age Related Macular Degeneration Market - IMG1

However, high cost associated with age related macular degeneration drugs is projected to impede the market growth in upcoming years. On the contrary, increase in R&D activities in age-related macular degeneration (AMD) treatment, and latest product approvals are expected to provide lucrative opportunities for the growth of the market in the near future.

The age-related macular degeneration (AMD) market is segmented into drug type, disease type, distribution channels and region. On the basis of drug type, the market is categorized into aflibercept, ranibizumab and others. On the basis of disease type, the market is bifurcated into dry age-related macular degeneration (AMD) and wet age-related macular degeneration (AMD). On the basis of distribution channels, the market is segmented into hospital pharmacy, retail pharmacy and online pharmacy. On the basis of region, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and Rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and Rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and Rest of LAMEA).

Major key players that operate in the global age-related macular degeneration (AMD) market are Regeneron Pharmaceuticals Inc., Novartis AG, F. Hoffmann-La Roche Ltd, Biogen, Bayer AG, Bausch Health Companies Inc, Coherus Biosciences Inc, Sanofi, Apellis Pharmaceuticals and Ionis Pharmaceuticals, Inc.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the age related macular degeneration (amd) market analysis from 2022 to 2032 to identify the prevailing age related macular degeneration (amd) market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the age related macular degeneration (amd) market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global age related macular degeneration (amd) market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Drug Type

  • Aflibercept
  • Ranibizumab
  • Others

By Disease Type

  • Wet Age Related Macular Degeneration (AMD)
  • Dry Age Related Macular Degeneration (AMD)

By Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • France
    • Germany
    • Italy
    • Spain
    • UK
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • Australia
    • India
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Key Market Players:

    • F. Hoffmann-La Roche Ltd.
    • Coherus Biosciences Inc
    • Biogen
    • Regeneron Pharmaceuticals Inc.
    • Ionis Pharmaceuticals, Inc.
    • Novartis AG
    • Bayer AG
    • Bausch Health Companies Inc.
    • Apellis Pharmaceuticals Inc.
    • Sanofi S.A.

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key market segments
  • 1.3. Key benefits to the stakeholders
  • 1.4. Research Methodology
    • 1.4.1. Primary research
    • 1.4.2. Secondary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top impacting factors
    • 3.2.2. Top investment pockets
  • 3.3. Porter's five forces analysis
    • 3.3.1. Bargaining power of suppliers
    • 3.3.2. Bargaining power of buyers
    • 3.3.3. Threat of substitutes
    • 3.3.4. Threat of new entrants
    • 3.3.5. Intensity of rivalry
  • 3.4. Market dynamics
    • 3.4.1. Drivers
      • 3.4.1.1. Increase in geriatric population
      • 3.4.1.2. Increase in incidences of age-related macular degeneration (AMD) across the globe
    • 3.4.2. Restraints
      • 3.4.2.1. High cost of treatment
    • 3.4.3. Opportunities
      • 3.4.3.1. Increase in number of pipelines drug
  • 3.5. COVID-19 Impact Analysis on the market

CHAPTER 4: AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DRUG TYPE

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. Aflibercept
    • 4.2.1. Key market trends, growth factors and opportunities
    • 4.2.2. Market size and forecast, by region
    • 4.2.3. Market share analysis by country
  • 4.3. Ranibizumab
    • 4.3.1. Key market trends, growth factors and opportunities
    • 4.3.2. Market size and forecast, by region
    • 4.3.3. Market share analysis by country
  • 4.4. Others
    • 4.4.1. Key market trends, growth factors and opportunities
    • 4.4.2. Market size and forecast, by region
    • 4.4.3. Market share analysis by country

CHAPTER 5: AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DISEASE TYPE

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. Wet Age Related Macular Degeneration (AMD)
    • 5.2.1. Key market trends, growth factors and opportunities
    • 5.2.2. Market size and forecast, by region
    • 5.2.3. Market share analysis by country
  • 5.3. Dry Age Related Macular Degeneration (AMD)
    • 5.3.1. Key market trends, growth factors and opportunities
    • 5.3.2. Market size and forecast, by region
    • 5.3.3. Market share analysis by country

CHAPTER 6: AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DISTRIBUTION CHANNEL

  • 6.1. Overview
    • 6.1.1. Market size and forecast
  • 6.2. Hospital Pharmacy
    • 6.2.1. Key market trends, growth factors and opportunities
    • 6.2.2. Market size and forecast, by region
    • 6.2.3. Market share analysis by country
  • 6.3. Retail Pharmacy
    • 6.3.1. Key market trends, growth factors and opportunities
    • 6.3.2. Market size and forecast, by region
    • 6.3.3. Market share analysis by country
  • 6.4. Online Pharmacy
    • 6.4.1. Key market trends, growth factors and opportunities
    • 6.4.2. Market size and forecast, by region
    • 6.4.3. Market share analysis by country

CHAPTER 7: AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY REGION

  • 7.1. Overview
    • 7.1.1. Market size and forecast By Region
  • 7.2. North America
    • 7.2.1. Key trends and opportunities
    • 7.2.2. Market size and forecast, by Drug Type
    • 7.2.3. Market size and forecast, by Disease Type
    • 7.2.4. Market size and forecast, by Distribution Channel
    • 7.2.5. Market size and forecast, by country
      • 7.2.5.1. U.S.
      • 7.2.5.1.1. Key market trends, growth factors and opportunities
      • 7.2.5.1.2. Market size and forecast, by Drug Type
      • 7.2.5.1.3. Market size and forecast, by Disease Type
      • 7.2.5.1.4. Market size and forecast, by Distribution Channel
      • 7.2.5.2. Canada
      • 7.2.5.2.1. Key market trends, growth factors and opportunities
      • 7.2.5.2.2. Market size and forecast, by Drug Type
      • 7.2.5.2.3. Market size and forecast, by Disease Type
      • 7.2.5.2.4. Market size and forecast, by Distribution Channel
      • 7.2.5.3. Mexico
      • 7.2.5.3.1. Key market trends, growth factors and opportunities
      • 7.2.5.3.2. Market size and forecast, by Drug Type
      • 7.2.5.3.3. Market size and forecast, by Disease Type
      • 7.2.5.3.4. Market size and forecast, by Distribution Channel
  • 7.3. Europe
    • 7.3.1. Key trends and opportunities
    • 7.3.2. Market size and forecast, by Drug Type
    • 7.3.3. Market size and forecast, by Disease Type
    • 7.3.4. Market size and forecast, by Distribution Channel
    • 7.3.5. Market size and forecast, by country
      • 7.3.5.1. France
      • 7.3.5.1.1. Key market trends, growth factors and opportunities
      • 7.3.5.1.2. Market size and forecast, by Drug Type
      • 7.3.5.1.3. Market size and forecast, by Disease Type
      • 7.3.5.1.4. Market size and forecast, by Distribution Channel
      • 7.3.5.2. Germany
      • 7.3.5.2.1. Key market trends, growth factors and opportunities
      • 7.3.5.2.2. Market size and forecast, by Drug Type
      • 7.3.5.2.3. Market size and forecast, by Disease Type
      • 7.3.5.2.4. Market size and forecast, by Distribution Channel
      • 7.3.5.3. Italy
      • 7.3.5.3.1. Key market trends, growth factors and opportunities
      • 7.3.5.3.2. Market size and forecast, by Drug Type
      • 7.3.5.3.3. Market size and forecast, by Disease Type
      • 7.3.5.3.4. Market size and forecast, by Distribution Channel
      • 7.3.5.4. Spain
      • 7.3.5.4.1. Key market trends, growth factors and opportunities
      • 7.3.5.4.2. Market size and forecast, by Drug Type
      • 7.3.5.4.3. Market size and forecast, by Disease Type
      • 7.3.5.4.4. Market size and forecast, by Distribution Channel
      • 7.3.5.5. UK
      • 7.3.5.5.1. Key market trends, growth factors and opportunities
      • 7.3.5.5.2. Market size and forecast, by Drug Type
      • 7.3.5.5.3. Market size and forecast, by Disease Type
      • 7.3.5.5.4. Market size and forecast, by Distribution Channel
      • 7.3.5.6. Rest of Europe
      • 7.3.5.6.1. Key market trends, growth factors and opportunities
      • 7.3.5.6.2. Market size and forecast, by Drug Type
      • 7.3.5.6.3. Market size and forecast, by Disease Type
      • 7.3.5.6.4. Market size and forecast, by Distribution Channel
  • 7.4. Asia-Pacific
    • 7.4.1. Key trends and opportunities
    • 7.4.2. Market size and forecast, by Drug Type
    • 7.4.3. Market size and forecast, by Disease Type
    • 7.4.4. Market size and forecast, by Distribution Channel
    • 7.4.5. Market size and forecast, by country
      • 7.4.5.1. China
      • 7.4.5.1.1. Key market trends, growth factors and opportunities
      • 7.4.5.1.2. Market size and forecast, by Drug Type
      • 7.4.5.1.3. Market size and forecast, by Disease Type
      • 7.4.5.1.4. Market size and forecast, by Distribution Channel
      • 7.4.5.2. Japan
      • 7.4.5.2.1. Key market trends, growth factors and opportunities
      • 7.4.5.2.2. Market size and forecast, by Drug Type
      • 7.4.5.2.3. Market size and forecast, by Disease Type
      • 7.4.5.2.4. Market size and forecast, by Distribution Channel
      • 7.4.5.3. Australia
      • 7.4.5.3.1. Key market trends, growth factors and opportunities
      • 7.4.5.3.2. Market size and forecast, by Drug Type
      • 7.4.5.3.3. Market size and forecast, by Disease Type
      • 7.4.5.3.4. Market size and forecast, by Distribution Channel
      • 7.4.5.4. India
      • 7.4.5.4.1. Key market trends, growth factors and opportunities
      • 7.4.5.4.2. Market size and forecast, by Drug Type
      • 7.4.5.4.3. Market size and forecast, by Disease Type
      • 7.4.5.4.4. Market size and forecast, by Distribution Channel
      • 7.4.5.5. South Korea
      • 7.4.5.5.1. Key market trends, growth factors and opportunities
      • 7.4.5.5.2. Market size and forecast, by Drug Type
      • 7.4.5.5.3. Market size and forecast, by Disease Type
      • 7.4.5.5.4. Market size and forecast, by Distribution Channel
      • 7.4.5.6. Rest of Asia-Pacific
      • 7.4.5.6.1. Key market trends, growth factors and opportunities
      • 7.4.5.6.2. Market size and forecast, by Drug Type
      • 7.4.5.6.3. Market size and forecast, by Disease Type
      • 7.4.5.6.4. Market size and forecast, by Distribution Channel
  • 7.5. LAMEA
    • 7.5.1. Key trends and opportunities
    • 7.5.2. Market size and forecast, by Drug Type
    • 7.5.3. Market size and forecast, by Disease Type
    • 7.5.4. Market size and forecast, by Distribution Channel
    • 7.5.5. Market size and forecast, by country
      • 7.5.5.1. Brazil
      • 7.5.5.1.1. Key market trends, growth factors and opportunities
      • 7.5.5.1.2. Market size and forecast, by Drug Type
      • 7.5.5.1.3. Market size and forecast, by Disease Type
      • 7.5.5.1.4. Market size and forecast, by Distribution Channel
      • 7.5.5.2. Saudi Arabia
      • 7.5.5.2.1. Key market trends, growth factors and opportunities
      • 7.5.5.2.2. Market size and forecast, by Drug Type
      • 7.5.5.2.3. Market size and forecast, by Disease Type
      • 7.5.5.2.4. Market size and forecast, by Distribution Channel
      • 7.5.5.3. South Africa
      • 7.5.5.3.1. Key market trends, growth factors and opportunities
      • 7.5.5.3.2. Market size and forecast, by Drug Type
      • 7.5.5.3.3. Market size and forecast, by Disease Type
      • 7.5.5.3.4. Market size and forecast, by Distribution Channel
      • 7.5.5.4. Rest of LAMEA
      • 7.5.5.4.1. Key market trends, growth factors and opportunities
      • 7.5.5.4.2. Market size and forecast, by Drug Type
      • 7.5.5.4.3. Market size and forecast, by Disease Type
      • 7.5.5.4.4. Market size and forecast, by Distribution Channel

CHAPTER 8: COMPETITIVE LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top winning strategies
  • 8.3. Product Mapping of Top 10 Player
  • 8.4. Competitive Dashboard
  • 8.5. Competitive Heatmap
  • 8.6. Top player positioning, 2022

CHAPTER 9: COMPANY PROFILES

  • 9.1. Regeneron Pharmaceuticals Inc.
    • 9.1.1. Company overview
    • 9.1.2. Key Executives
    • 9.1.3. Company snapshot
    • 9.1.4. Operating business segments
    • 9.1.5. Product portfolio
    • 9.1.6. Business performance
  • 9.2. Novartis AG
    • 9.2.1. Company overview
    • 9.2.2. Key Executives
    • 9.2.3. Company snapshot
    • 9.2.4. Operating business segments
    • 9.2.5. Product portfolio
    • 9.2.6. Business performance
    • 9.2.7. Key strategic moves and developments
  • 9.3. F. Hoffmann-La Roche Ltd.
    • 9.3.1. Company overview
    • 9.3.2. Key Executives
    • 9.3.3. Company snapshot
    • 9.3.4. Operating business segments
    • 9.3.5. Product portfolio
    • 9.3.6. Business performance
    • 9.3.7. Key strategic moves and developments
  • 9.4. Biogen
    • 9.4.1. Company overview
    • 9.4.2. Key Executives
    • 9.4.3. Company snapshot
    • 9.4.4. Operating business segments
    • 9.4.5. Product portfolio
    • 9.4.6. Business performance
    • 9.4.7. Key strategic moves and developments
  • 9.5. Bayer AG
    • 9.5.1. Company overview
    • 9.5.2. Key Executives
    • 9.5.3. Company snapshot
    • 9.5.4. Operating business segments
    • 9.5.5. Product portfolio
    • 9.5.6. Business performance
  • 9.6. Coherus Biosciences Inc
    • 9.6.1. Company overview
    • 9.6.2. Key Executives
    • 9.6.3. Company snapshot
    • 9.6.4. Operating business segments
    • 9.6.5. Product portfolio
    • 9.6.6. Business performance
    • 9.6.7. Key strategic moves and developments
  • 9.7. Sanofi S.A.
    • 9.7.1. Company overview
    • 9.7.2. Key Executives
    • 9.7.3. Company snapshot
    • 9.7.4. Operating business segments
    • 9.7.5. Product portfolio
    • 9.7.6. Business performance
  • 9.8. Apellis Pharmaceuticals Inc.
    • 9.8.1. Company overview
    • 9.8.2. Key Executives
    • 9.8.3. Company snapshot
    • 9.8.4. Operating business segments
    • 9.8.5. Product portfolio
    • 9.8.6. Business performance
    • 9.8.7. Key strategic moves and developments
  • 9.9. Bausch Health Companies Inc.
    • 9.9.1. Company overview
    • 9.9.2. Key Executives
    • 9.9.3. Company snapshot
    • 9.9.4. Operating business segments
    • 9.9.5. Product portfolio
    • 9.9.6. Business performance
  • 9.10. Ionis Pharmaceuticals, Inc.
    • 9.10.1. Company overview
    • 9.10.2. Key Executives
    • 9.10.3. Company snapshot
    • 9.10.4. Operating business segments
    • 9.10.5. Product portfolio
    • 9.10.6. Business performance

LIST OF TABLES

  • TABLE 01. GLOBAL AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 02. AGE RELATED MACULAR DEGENERATION (AMD) MARKET FOR AFLIBERCEPT, BY REGION, 2022-2032 ($MILLION)
  • TABLE 03. AGE RELATED MACULAR DEGENERATION (AMD) MARKET FOR RANIBIZUMAB, BY REGION, 2022-2032 ($MILLION)
  • TABLE 04. AGE RELATED MACULAR DEGENERATION (AMD) MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 05. GLOBAL AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
  • TABLE 06. AGE RELATED MACULAR DEGENERATION (AMD) MARKET FOR WET AGE RELATED MACULAR DEGENERATION (AMD), BY REGION, 2022-2032 ($MILLION)
  • TABLE 07. AGE RELATED MACULAR DEGENERATION (AMD) MARKET FOR DRY AGE RELATED MACULAR DEGENERATION (AMD), BY REGION, 2022-2032 ($MILLION)
  • TABLE 08. GLOBAL AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 09. AGE RELATED MACULAR DEGENERATION (AMD) MARKET FOR HOSPITAL PHARMACY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 10. AGE RELATED MACULAR DEGENERATION (AMD) MARKET FOR RETAIL PHARMACY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 11. AGE RELATED MACULAR DEGENERATION (AMD) MARKET FOR ONLINE PHARMACY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 12. AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 13. NORTH AMERICA AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 14. NORTH AMERICA AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
  • TABLE 15. NORTH AMERICA AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 16. NORTH AMERICA AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 17. U.S. AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 18. U.S. AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
  • TABLE 19. U.S. AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 20. CANADA AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 21. CANADA AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
  • TABLE 22. CANADA AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 23. MEXICO AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 24. MEXICO AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
  • TABLE 25. MEXICO AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 26. EUROPE AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 27. EUROPE AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
  • TABLE 28. EUROPE AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 29. EUROPE AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 30. FRANCE AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 31. FRANCE AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
  • TABLE 32. FRANCE AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 33. GERMANY AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 34. GERMANY AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
  • TABLE 35. GERMANY AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 36. ITALY AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 37. ITALY AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
  • TABLE 38. ITALY AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 39. SPAIN AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 40. SPAIN AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
  • TABLE 41. SPAIN AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 42. UK AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 43. UK AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
  • TABLE 44. UK AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 45. REST OF EUROPE AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 46. REST OF EUROPE AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
  • TABLE 47. REST OF EUROPE AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 48. ASIA-PACIFIC AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 49. ASIA-PACIFIC AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
  • TABLE 50. ASIA-PACIFIC AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 51. ASIA-PACIFIC AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 52. CHINA AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 53. CHINA AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
  • TABLE 54. CHINA AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 55. JAPAN AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 56. JAPAN AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
  • TABLE 57. JAPAN AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 58. AUSTRALIA AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 59. AUSTRALIA AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
  • TABLE 60. AUSTRALIA AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 61. INDIA AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 62. INDIA AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
  • TABLE 63. INDIA AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 64. SOUTH KOREA AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 65. SOUTH KOREA AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
  • TABLE 66. SOUTH KOREA AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 67. REST OF ASIA-PACIFIC AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 68. REST OF ASIA-PACIFIC AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
  • TABLE 69. REST OF ASIA-PACIFIC AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 70. LAMEA AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 71. LAMEA AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
  • TABLE 72. LAMEA AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 73. LAMEA AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 74. BRAZIL AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 75. BRAZIL AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
  • TABLE 76. BRAZIL AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 77. SAUDI ARABIA AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 78. SAUDI ARABIA AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
  • TABLE 79. SAUDI ARABIA AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 80. SOUTH AFRICA AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 81. SOUTH AFRICA AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
  • TABLE 82. SOUTH AFRICA AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 83. REST OF LAMEA AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
  • TABLE 84. REST OF LAMEA AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
  • TABLE 85. REST OF LAMEA AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 86. REGENERON PHARMACEUTICALS INC.: KEY EXECUTIVES
  • TABLE 87. REGENERON PHARMACEUTICALS INC.: COMPANY SNAPSHOT
  • TABLE 88. REGENERON PHARMACEUTICALS INC.: PRODUCT SEGMENTS
  • TABLE 89. REGENERON PHARMACEUTICALS INC.: PRODUCT PORTFOLIO
  • TABLE 90. NOVARTIS AG: KEY EXECUTIVES
  • TABLE 91. NOVARTIS AG: COMPANY SNAPSHOT
  • TABLE 92. NOVARTIS AG: PRODUCT SEGMENTS
  • TABLE 93. NOVARTIS AG: PRODUCT PORTFOLIO
  • TABLE 94. NOVARTIS AG: KEY STRATERGIES
  • TABLE 95. F. HOFFMANN-LA ROCHE LTD.: KEY EXECUTIVES
  • TABLE 96. F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT
  • TABLE 97. F. HOFFMANN-LA ROCHE LTD.: PRODUCT SEGMENTS
  • TABLE 98. F. HOFFMANN-LA ROCHE LTD.: PRODUCT PORTFOLIO
  • TABLE 99. F. HOFFMANN-LA ROCHE LTD.: KEY STRATERGIES
  • TABLE 100. BIOGEN: KEY EXECUTIVES
  • TABLE 101. BIOGEN: COMPANY SNAPSHOT
  • TABLE 102. BIOGEN: PRODUCT SEGMENTS
  • TABLE 103. BIOGEN: PRODUCT PORTFOLIO
  • TABLE 104. BIOGEN: KEY STRATERGIES
  • TABLE 105. BAYER AG: KEY EXECUTIVES
  • TABLE 106. BAYER AG: COMPANY SNAPSHOT
  • TABLE 107. BAYER AG: PRODUCT SEGMENTS
  • TABLE 108. BAYER AG: PRODUCT PORTFOLIO
  • TABLE 109. COHERUS BIOSCIENCES INC: KEY EXECUTIVES
  • TABLE 110. COHERUS BIOSCIENCES INC: COMPANY SNAPSHOT
  • TABLE 111. COHERUS BIOSCIENCES INC: PRODUCT SEGMENTS
  • TABLE 112. COHERUS BIOSCIENCES INC: PRODUCT PORTFOLIO
  • TABLE 113. COHERUS BIOSCIENCES INC: KEY STRATERGIES
  • TABLE 114. SANOFI S.A.: KEY EXECUTIVES
  • TABLE 115. SANOFI S.A.: COMPANY SNAPSHOT
  • TABLE 116. SANOFI S.A.: PRODUCT SEGMENTS
  • TABLE 117. SANOFI S.A.: PRODUCT PORTFOLIO
  • TABLE 118. APELLIS PHARMACEUTICALS INC.: KEY EXECUTIVES
  • TABLE 119. APELLIS PHARMACEUTICALS INC.: COMPANY SNAPSHOT
  • TABLE 120. APELLIS PHARMACEUTICALS INC.: PRODUCT SEGMENTS
  • TABLE 121. APELLIS PHARMACEUTICALS INC.: PRODUCT PORTFOLIO
  • TABLE 122. APELLIS PHARMACEUTICALS INC.: KEY STRATERGIES
  • TABLE 123. BAUSCH HEALTH COMPANIES INC.: KEY EXECUTIVES
  • TABLE 124. BAUSCH HEALTH COMPANIES INC.: COMPANY SNAPSHOT
  • TABLE 125. BAUSCH HEALTH COMPANIES INC.: PRODUCT SEGMENTS
  • TABLE 126. BAUSCH HEALTH COMPANIES INC.: PRODUCT PORTFOLIO
  • TABLE 127. IONIS PHARMACEUTICALS, INC.: KEY EXECUTIVES
  • TABLE 128. IONIS PHARMACEUTICALS, INC.: COMPANY SNAPSHOT
  • TABLE 129. IONIS PHARMACEUTICALS, INC.: PRODUCT SEGMENTS
  • TABLE 130. IONIS PHARMACEUTICALS, INC.: PRODUCT PORTFOLIO

LIST OF FIGURES

  • FIGURE 01. AGE RELATED MACULAR DEGENERATION (AMD) MARKET, 2022-2032
  • FIGURE 02. SEGMENTATION OF AGE RELATED MACULAR DEGENERATION (AMD) MARKET, 2022-2032
  • FIGURE 03. TOP INVESTMENT POCKETS IN AGE RELATED MACULAR DEGENERATION (AMD) MARKET (2023-2032)
  • FIGURE 04. LOW BARGAINING POWER OF SUPPLIERS
  • FIGURE 05. LOW BARGAINING POWER OF BUYERS
  • FIGURE 06. LOW THREAT OF SUBSTITUTES
  • FIGURE 07. LOW THREAT OF NEW ENTRANTS
  • FIGURE 08. LOW INTENSITY OF RIVALRY
  • FIGURE 09. DRIVERS, RESTRAINTS AND OPPORTUNITIES: GLOBALAGE RELATED MACULAR DEGENERATION (AMD) MARKET
  • FIGURE 10. AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DRUG TYPE, 2022(%)
  • FIGURE 11. COMPARATIVE SHARE ANALYSIS OF AGE RELATED MACULAR DEGENERATION (AMD) MARKET FOR AFLIBERCEPT, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 12. COMPARATIVE SHARE ANALYSIS OF AGE RELATED MACULAR DEGENERATION (AMD) MARKET FOR RANIBIZUMAB, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 13. COMPARATIVE SHARE ANALYSIS OF AGE RELATED MACULAR DEGENERATION (AMD) MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 14. AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DISEASE TYPE, 2022(%)
  • FIGURE 15. COMPARATIVE SHARE ANALYSIS OF AGE RELATED MACULAR DEGENERATION (AMD) MARKET FOR WET AGE RELATED MACULAR DEGENERATION (AMD), BY COUNTRY 2022 AND 2032(%)
  • FIGURE 16. COMPARATIVE SHARE ANALYSIS OF AGE RELATED MACULAR DEGENERATION (AMD) MARKET FOR DRY AGE RELATED MACULAR DEGENERATION (AMD), BY COUNTRY 2022 AND 2032(%)
  • FIGURE 17. AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DISTRIBUTION CHANNEL, 2022(%)
  • FIGURE 18. COMPARATIVE SHARE ANALYSIS OF AGE RELATED MACULAR DEGENERATION (AMD) MARKET FOR HOSPITAL PHARMACY, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 19. COMPARATIVE SHARE ANALYSIS OF AGE RELATED MACULAR DEGENERATION (AMD) MARKET FOR RETAIL PHARMACY, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 20. COMPARATIVE SHARE ANALYSIS OF AGE RELATED MACULAR DEGENERATION (AMD) MARKET FOR ONLINE PHARMACY, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 21. AGE RELATED MACULAR DEGENERATION (AMD) MARKET BY REGION, 2022
  • FIGURE 22. U.S. AGE RELATED MACULAR DEGENERATION (AMD) MARKET, 2022-2032 ($MILLION)
  • FIGURE 23. CANADA AGE RELATED MACULAR DEGENERATION (AMD) MARKET, 2022-2032 ($MILLION)
  • FIGURE 24. MEXICO AGE RELATED MACULAR DEGENERATION (AMD) MARKET, 2022-2032 ($MILLION)
  • FIGURE 25. FRANCE AGE RELATED MACULAR DEGENERATION (AMD) MARKET, 2022-2032 ($MILLION)
  • FIGURE 26. GERMANY AGE RELATED MACULAR DEGENERATION (AMD) MARKET, 2022-2032 ($MILLION)
  • FIGURE 27. ITALY AGE RELATED MACULAR DEGENERATION (AMD) MARKET, 2022-2032 ($MILLION)
  • FIGURE 28. SPAIN AGE RELATED MACULAR DEGENERATION (AMD) MARKET, 2022-2032 ($MILLION)
  • FIGURE 29. UK AGE RELATED MACULAR DEGENERATION (AMD) MARKET, 2022-2032 ($MILLION)
  • FIGURE 30. REST OF EUROPE AGE RELATED MACULAR DEGENERATION (AMD) MARKET, 2022-2032 ($MILLION)
  • FIGURE 31. CHINA AGE RELATED MACULAR DEGENERATION (AMD) MARKET, 2022-2032 ($MILLION)
  • FIGURE 32. JAPAN AGE RELATED MACULAR DEGENERATION (AMD) MARKET, 2022-2032 ($MILLION)
  • FIGURE 33. AUSTRALIA AGE RELATED MACULAR DEGENERATION (AMD) MARKET, 2022-2032 ($MILLION)
  • FIGURE 34. INDIA AGE RELATED MACULAR DEGENERATION (AMD) MARKET, 2022-2032 ($MILLION)
  • FIGURE 35. SOUTH KOREA AGE RELATED MACULAR DEGENERATION (AMD) MARKET, 2022-2032 ($MILLION)
  • FIGURE 36. REST OF ASIA-PACIFIC AGE RELATED MACULAR DEGENERATION (AMD) MARKET, 2022-2032 ($MILLION)
  • FIGURE 37. BRAZIL AGE RELATED MACULAR DEGENERATION (AMD) MARKET, 2022-2032 ($MILLION)
  • FIGURE 38. SAUDI ARABIA AGE RELATED MACULAR DEGENERATION (AMD) MARKET, 2022-2032 ($MILLION)
  • FIGURE 39. SOUTH AFRICA AGE RELATED MACULAR DEGENERATION (AMD) MARKET, 2022-2032 ($MILLION)
  • FIGURE 40. REST OF LAMEA AGE RELATED MACULAR DEGENERATION (AMD) MARKET, 2022-2032 ($MILLION)
  • FIGURE 41. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 42. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 43. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 44. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 45. COMPETITIVE DASHBOARD
  • FIGURE 46. COMPETITIVE HEATMAP: AGE RELATED MACULAR DEGENERATION (AMD) MARKET
  • FIGURE 47. TOP PLAYER POSITIONING, 2022
  • FIGURE 48. REGENERON PHARMACEUTICALS INC.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 49. NOVARTIS AG: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 50. NOVARTIS AG: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 51. NOVARTIS AG: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 52. F. HOFFMANN-LA ROCHE LTD.: SALES REVENUE, 2020-2022 ($MILLION)
  • FIGURE 53. F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 54. BIOGEN: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 55. BIOGEN: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 56. BAYER AG: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 57. BAYER AG: RESEARCH & DEVELOPMENT EXPENDITURE, 2020-2022 ($MILLION)
  • FIGURE 58. BAYER AG: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 59. BAYER AG: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 60. COHERUS BIOSCIENCES INC: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 61. COHERUS BIOSCIENCES INC: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 62. SANOFI S.A.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 63. SANOFI S.A.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 64. SANOFI S.A.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 65. APELLIS PHARMACEUTICALS INC.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 66. BAUSCH HEALTH COMPANIES INC.: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 67. BAUSCH HEALTH COMPANIES INC.: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 68. BAUSCH HEALTH COMPANIES INC.: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 69. IONIS PHARMACEUTICALS, INC.: NET REVENUE, 2020-2022 ($MILLION)